The COBL Knockout Raji Polyclonal Cells are a polyclonal population of Raji B lymphoblastoid cells genetically engineered using CRISPR/Cas9-mediated gene disruption to ablate functional expression of the COBL gene. This loss-of-function model is provided as a heterogeneous pool of edited cells, enabling robust analysis of COBL-dependent phenotypes in a B lymphocyte background. By eliminating the Cordon-bleu actin nucleation factor, the cells permit investigation of cytoskeletal dynamics, cell motility, and immune synapse assembly. The polyclonal format avoids clonal artifacts and captures a range of editing outcomes, offering a versatile tool for studies requiring population-level responses. Researchers can employ this reagent in diverse functional assays to dissect COBL??s role in cellular architecture and signal transduction, with versatile applications in cancer biology and immunology contexts.
Raji cells are an EBV-positive Burkitt’s lymphoma-derived B lymphoblastoid line that maintains many characteristics of mature B lymphocytes, including surface immunoglobulin expression, immune synapse formation, and robust proliferative capacity. As a model for humoral immunity and B-cell malignancies, Raji cells are extensively used to study antigen presentation, B-cell receptor signaling, and the tumor microenvironment. Their derivation from lymphomatous tissue provides a relevant system for examining drivers of lymphoma invasion and metastasis. Additionally, Raji cells are amenable to standard molecular biology workflows, including transfection, lentiviral transduction, and CRISPR/Cas9 delivery, making them a practical host for targeted gene knockout. This established cell line offers a well-characterized platform to explore how COBL disruption impacts B lymphocyte functions and pathological behaviors.
COBL encodes Cordon-bleu, a multi-WH2 domain-containing actin nucleation factor that directly promotes actin filament assembly independently of the ARP2/3 complex. Acting downstream of Rho family GTPases such as Rac1, Cdc42, and RhoA, COBL cooperates with the WAVE regulatory complex, which includes Abi1, Nap1, and Sra1, to coordinate localized actin polymerization at membrane protrusion sites. COBL interacts with monomeric G-actin to seed new filaments and collaborates with mDia formins to elongate unbranched actin structures. Its activity is regulated by Notch signaling and Rho GTPase cascades, linking extracellular cues to cytoskeletal remodeling. Downstream, COBL-dependent actin nucleation generates lamellipodia, filopodia, and other protrusive structures essential for cell morphogenesis, migration, and adhesion.
In Raji B lymphocytes, COBL knockout is anticipated to compromise actin-dependent processes critical for immune cell function, including uropod formation, chemokine-directed migration, and assembly of the immunological synapse. Disrupted actin dynamics may impair B-cell receptor clustering and downstream phospho-signaling events, such as those mediated by Syk and PLC??2, potentially attenuating proliferation and survival signals in lymphoma cells. Given the association of COBL with cancer metastasis and neurodevelopmental disorders, this knockout model enables interrogation of cytoskeletal contributions to B-cell malignancy progression and invasiveness. The Raji background provides a clinically relevant context to evaluate how loss of COBL-mediated actin regulation influences lymphoma cell behavior, extracellular matrix interactions, and responses to therapeutic agents targeting the cytoskeleton.
Typical applications include B-cell migration assays using Transwell chambers, where COBL knockout effects on chemokine-driven motility can be quantified. Immune synapse imaging by fluorescence microscopy allows visualization of actin reorganization at the T-cell?CB-cell contact zone, while cell adhesion assays probe interactions with fibronectin or ICAM-1 substrates. The cells are suitable for biochemical analyses such as Western blotting and RT-qPCR to confirm COBL disruption and assess pathway alterations, and flow cytometry can monitor phosphorylated signaling intermediates. Cytoskeletal drug testing, including exposure to actin polymerization inhibitors, provides a platform for investigating pharmacologic vulnerabilities in lymphoma. For detailed technical specifications, please contact Ascent Research.
